THE ROLE OF BRACHYTHERAPY IN TREATMENT FOR ESOPHAGEAL CANCER

2017 ◽  
Vol 63 (4) ◽  
pp. 660-665
Author(s):  
Yelena Tyuryaeva
Keyword(s):  
Esophageal Cancer ◽  
Critical Review ◽  
Palliative Treatment ◽  
Combined Treatment ◽  
Neoadjuvant Treatment ◽  
Early Esophageal Cancer ◽  
Separate Section ◽  
Treatment Regimens ◽  
Contradictory Data

The article is devoted to various aspects of the use of intraluminal brachytherapy (IB) in treatment for esophageal cancer (EC). A critical review of the use of IB as a component of combined radiotherapy/chemoradiotherapy in neoadjuvant treatment regimens, for definitive CRT, as well as in palliative treatment of non-operable tumors of this localization is given. The contradictory data on the effectiveness of brachytherapy with locally distributed, inoperable EC are summarized. A separate section relates to the prospects for incorporating brachytherapy into combined treatment of early esophageal cancer. Carried out analysis testifies to the necessity of standardization of summary and daily doses of irradiation depending on the indications to the IB.

Role of Lugol Dye Endoscopy in the Diagnosis of Early Esophageal Cancer

Endoscopy ◽  
1990 ◽  
Vol 22 (01) ◽  
pp. 12-16 ◽  
Author(s):  
A. Misumi ◽  
K. Harada ◽  
A. Murakami ◽  
K. Arima ◽  
H. Kondo ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Early Esophageal Cancer

scholarly journals The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3703
Author(s):  
Lily Nguyen ◽  
Daniela Schilling ◽  
Sophie Dobiasch ◽  
Susanne Raulefs ◽  
Marina Santiago Franco ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Radiation Treatment ◽  
Neoadjuvant Treatment ◽  
Blood Biomarkers ◽  
Curative Intent ◽  
Treatment Regimens ◽  
Tumor Bearing ◽  
Radiation Induced ◽  
Induced Changes

Today, pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide with a five-year overall survival rate of less than 7%. Only 15–20% of patients are eligible for curative intent surgery at the time of diagnosis. Therefore, neoadjuvant treatment regimens have been introduced in order to downsize the tumor by chemotherapy and radiotherapy. To further increase the efficacy of radiotherapy, novel molecular biomarkers are urgently needed to define the subgroup of pancreatic cancer patients who would benefit most from radiotherapy. MicroRNAs (miRNAs) could have the potential to serve as novel predictive and prognostic biomarkers in patients with pancreatic cancer. In the present article, the role of miRNAs as blood biomarkers, which are associated with either radioresistance or radiation-induced changes of miRNAs in pancreatic cancer, is discussed. Furthermore, the manuscript provides own data of miRNAs identified in a pancreatic cancer mouse model as well as radiation-induced miRNA changes in the plasma of tumor-bearing mice.

scholarly journals Role of endoscopic therapy in early esophageal cancer

2018 ◽  
Vol 24 (35) ◽  
pp. 3965-3973 ◽  
Author(s):  
Sonika Malik ◽  
Gautam Sharma ◽  
Madhusudhan R Sanaka ◽  
Prashanthi N Thota
Keyword(s):  
Esophageal Cancer ◽  
Endoscopic Therapy ◽  
Early Esophageal Cancer
Sign in / Sign up

Export Citation Format

Share Document